Back to search
FDAFDA · Food and drugs·Recall number D-0765-2022

IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmaceuticals, USA, Inc., North Wales, PA 19454, NDC 0703-4154-11.

Published April 20, 2022 · Recall initiated: March 29, 2022

Summary

FDA records drug Class I recall D-0765-2022, published April 20, 2022 and initiated March 29, 2022. Recalling firm: Teva Pharmaceuticals USA Inc; Status: Terminated; Reported quantity: 1565 vials; Lot: Lot #: 31329657B, Exp. Date 08/2023. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Particulate Matter: Product was found to contain silica and iron oxide

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA Inc
Distributor
Nationwide within the United States
Lot
Lot #: 31329657B, Exp. Date 08/2023
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmaceuticals, USA, Inc., North Wales, PA 19454, NDC 0703-4154-11. recalled?

Yes. FDA published recall D-0765-2022 on April 20, 2022. Reported hazard: Presence of Particulate Matter: Product was found to contain silica and iron oxide

What should I do if I have this product?

Voluntary: Firm initiated · Letter